Guangzhou Zhiyi Biotech
A leading LBPs company in China
- Dedicating to develop accessible drugs to benefit more patients
Relationship research between pathogenic microorganisms and diseases
Isolation and identification new functional strains
Developing innovative microbiome-based drugs - Based on R&D of Bacteroides fragilis, ZYBio has acquired the know-how from strains to LBP.
- 5 Major Milestones Leading the LBP Industry, with Advanced Clinical Progress:
SK08:
Phase III for IBS-D treatment
Phase I completed for UC treatment
Phase I completed for pediatric acute diarrhea caused by rotavirus
Phase I in combination with PD-1 antibodies for advanced solid tumors
SK10:
Phase I completed under FDA for Chemotherapy-Induced Diarrhea (CID)
- Dedicating to develop accessible drugs to benefit more patients
Guangzhou Proforcare
Guangzhou Proforcare Pharmaceuticals Inc., a subsidiary of Zhiyi Biotech, leverages Southern China's largest probiotic library to deliver high-quality microbial solutions. With 8,000m² of labs and GMP-like facilities for commercial-scale production, Proforcare provides comprehensive services including development, manufacturing, supply chain management, and technical support to meet diverse client needs.
